3.29
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Helix BioMedix
Its shares trade under the ticker HXBM. It has been listed since 25 July 2000. In the fiscal year to 31 December 2025, it reported revenue of $807,193 and a net loss of $551,512. At that date it held total assets of $1.7m and shareholders' equity of $1.5m.
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington. The company went IPO on 2000-07-25. The Company’s lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. The company is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. The company is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the body’s innate immunity.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 25 Jul 2000
- Employees
- 8
- Website
- helixbiomedix.com ↗
Leadership
Pay as last reported
- Mr. R. Stephen BeattyChairman of the Board, since 1999$414,350
- Ms. Robin CarmichaelPresident, Chief Executive Officer, Director, since 2007
- Mr. John CliffordIndependent Director
- Mr. Richard CohenIndependent Director
- Mr. William GoolsbeeIndependent Director
- Mr. Lawrence JonesIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HB4208 is a deoxyribonucleic damage response enzyme for topical treatment of Xeroderma Pigmentosum.
- Helix BioMedix has a proprietary library of bioactive peptides based on innate immunity.
- The company's intellectual property portfolio offers multiple commercialization pathways in dermatology.
Weaknesses
- The company employs only 8 full-time employees, limiting operational capacity.
- Helix BioMedix went public in 2000, indicating limited market presence.
- The focus on rare dermatological diseases restricts market size and revenue potential.
Opportunities
- Expanding into aesthetic dermatology and personal care from Rx dermatology pathways.
- Developing new treatment options for dermatologic conditions with bioactive small molecules.
- Transforming skin condition treatment through elegant topical formulations.
Threats
- Rare genetic disorders like Xeroderma Pigmentosum have limited patient populations.
- Biopharmaceutical development faces high regulatory hurdles and costs.
- Competition in dermatology may emerge from larger pharmaceutical companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.